Results 181 to 190 of about 41,260 (220)

Streptomyces as a Prominent Resource of Future Anti-MRSA Drugs [PDF]

Frontiers in Microbiology, 2018
Staphylococcus aureus résistant à la méthicilline (SARM) constitue une menace importante pour la santé car ils ont tendance à causer des infections graves dans les populations vulnérables et sont difficiles à traiter en raison d'une gamme limitée d'antibiotiques efficaces et de leur capacité à former un biofilm. Ces organismes étaient autrefois limités
Kok Gan Chan, Learn-Han Lee, Priyia Pusparajah   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Structure–activity relationship of indoloquinoline analogs anti-MRSA

Bioorganic and Medicinal Chemistry Letters, 2015
Indolo[3,2-b]quinoline analogs (3a-3s), 4-(acridin-9-ylamino) phenol hydrochloride (4), benzofuro[3,2-b]quinoline (3t), indeno[1,2-b]quinolines (3u and 3v) have been synthesized. Those compounds were found to exhibit anti-bacterial activity towards Methicillin-resistant Staphylococcus aureus (anti-MRSA activity). Structure-activity relationship studies
Teruo Kuroda
exaly   +3 more sources

Novel dithiocarbamate carbapenems with anti-MRSA activity

Bioorganic & Medicinal Chemistry, 1998
A new series of 1beta-methyl carbapenems, in which a disubstituted-aminothiocarbonylthio moiety was attached to the C-2 position of the carbapenem nucleus, were prepared and evaluated for anti-MRSA activity. These derivatives showed good in vitro antibacterial activity against high-level MRSA, and the finding of good affinity for PBP-2' supported these
N, Ohtake, H, Imamura, H, Jona, H, Kiyonaga, A, Shimizu, M, Moriya, H, Sato, M, Nakano, R, Ushijima, S, Nakagawa   +9 more
openaire   +2 more sources

The anti-MRSA resource: a comprehensive archive of anti-MRSA peptides and essential oils

Journal of Biomolecular Structure and Dynamics
Methicillin-resistant Staphylococcus aureus (MRSA), a major cause of fatalities due to Antimicrobial Resistance (AMR), can act as an opportunistic pathogen despite being part of the normal human flora. MRSA infections, such as skin infections, pneumonia, sepsis, and surgical site infections, have risen significantly, with bloodstream infection cases ...
Rajat Kumar Mondal, Ananya Anurag Anand, Debarup Sen, Sintu Kumar Samanta   +3 more
openaire   +2 more sources

Dicationic dithiocarbamate carbapenems with anti-MRSA activity

Bioorganic & Medicinal Chemistry, 2001
A new class of 1 beta-methylcarbapenems bearing a doubly quaternarized 1,4-diazabicyclooctane (DABCO) substituted dithiocarbamate moiety at the C-2 side chain was prepared, and the biological profiles of the compounds, including in vitro and in vivo anti-MRSA activity and DHP-I susceptibility, were evaluated to identify a carbapenem derivative that was
H, Imamura, N, Ohtake, H, Jona, A, Shimizu, M, Moriya, H, Sato, Y, Sugimoto, C, Ikeura, H, Kiyonaga, M, Nakano, R, Nagano, S, Abe, K, Yamada, T, Hashizume, H, Morishima   +14 more
openaire   +2 more sources

A Pilot Study of an Anti-MRSA Bio-Engineered Lacteal Complex (Anti-MRSA BLC) in a Murine Septicemia Model

Immunopharmacology and Immunotoxicology, 2006
Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen of humans and other animals, causing septicemia, abcessation, toxemia, and other infectious diseases. Refined bioengineered lacteal complex (BLC), made specifically against MRSA, is a novel complex of low molecular weight immunogenic and antimicrobial molecules.
Jesse A, Stoff, David E, Nix, D W, DeYoung   +2 more
openaire   +2 more sources

Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy

Expert Opinion on Investigational Drugs, 2007
Ceftobiprole is the first of the investigational beta-lactam antibiotics with in vitro activity against methicillin-resistant staphylococci to reach and complete Phase III therapeutic trials. Its antibacterial spectrum includes methicillin-resistant Staphylococcus aureus (MRSA), Enterococcus faecalis, penicillin-resistant streptococci and many Gram ...
Karen Bush, Mark Macielag, Gary J Noel
exaly   +3 more sources

Anti-MRSA β-lactams in development

Current Opinion in Pharmacology, 2006
Ceftobiprole medocaril, the most advanced of the anti-MRSA (methicillin-resistant Staphylococcus aureus) beta-lactams in clinical development, has recently completed its first Phase III clinical trial, and has demonstrated non-inferiority to vancomycin. Phase II clinical trials have been initiated with PPI0903, which is, like ceftobiprole medocaril, an
openaire   +2 more sources

Quinoline and cyanine dyes—putative anti-MRSA drugs

International Journal of Antimicrobial Agents, 2003
One way in which drug-resistant bacteria may be attacked is to screen new series of candidate compounds. Quaternary quinoline compounds and dyes were studied by Carl Browning (1887-1972) and Julius Cohen (1859-1935). A remarkable part of Browning and Cohen's work was the early development of structure-activity relationships for their series of ...
Wainwright, M., Kristiansen, J.E.
openaire   +3 more sources

Ceftaroline: a Cephalosporin with Anti-MRSA Activity

Clinical Microbiology Newsletter, 2011
Abstract Ceftaroline is a cephalosporin antibiotic with broad-spectrum activity against gram-positive and gram-negative bacteria, including contemporary resistant gram-positive phenotypes, such as methicillin-resistant Staphylococcus aureus (MRSA), multidrug-resistant Streptococcus pneumoniae , and penicillin-resistant S. pneumoniae .
Cheung Yee, Donald Biek, Kevin Krause, Gregory Williams   +3 more
openaire   +1 more source